Cephalon, Inc. (CEPH) to Acquire Gemin X Pharmaceuticals, Inc. for $225 Million; up to $300 Million in Milestones
3/22/2011 6:42:51 AM
More...
|
Gemin X Pharmaceuticals, Inc. Closes $8 Million Series E Financing
8/4/2010 12:25:04 PM
More...
|
Gemin X Pharmaceuticals, Inc. Announces $16 Million Series D Financing
4/20/2010 6:37:01 AM
More...
|
Gemin X Pharmaceuticals, Inc. Completes Patient Enrollment in Phase 2 Clinical Study of Obatoclax for First-Line Treatment of Small Cell Lung Cancer
3/29/2010 9:36:13 AM
More...
|
Gemin X Pharmaceuticals, Inc. Initiates Phase 2 Clinical Study of Obatoclax in Combination with Standard Chemotherapy for First-Line Treatment of Small Cell Lung Cancer
3/3/2009 9:27:36 AM
More...
|
Gemin X Pharmaceuticals, Inc. Presents New Data on Obatoclax at the American Society of Hematology Meeting
12/9/2008 11:39:57 AM
More...
|
Gemin X Pharmaceuticals, Inc. Announces Data Presentations for its Novel, Targeted Cancer Therapy Obatoclax at the 50th Annual American Society of Hematology Meeting and Exposition
12/2/2008 9:39:28 AM
More...
|
Gemin X Pharmaceuticals, Inc. Pan Bcl-2 Inhibitor Obatoclax Demonstrates Biological and Clinical Activity in Heavily Pre-Treated Patients with Advanced Chronic Lymphocytic Leukemia
10/28/2008 11:02:55 AM
More...
|
Key Data Presented for Gemin X Pharmaceuticals, Inc. Programs at the 20th Annual ENA Symposium
10/24/2008 10:00:10 AM
More...
|
Gemin X Pharmaceuticals, Inc. to Present at the 7th Annual Biotechnology Industry Organization (BIO) Investor Forum
10/22/2008 10:42:21 AM
More...
|
|